


URINARY TRACT INFECTION (UTI)

ALGORITHM- UTI Testing



Intended for:

- Patients with presumed UTI
- Greater than 60days of age

NOT intended for:

- Known urologic anomalies
- Chronic/complex conditions (ie. spinabifida, self cath, hardware, etc.)
- Recent urinary tract instrumentation placement
- Critical Illness
- Immunocompromised

***Index of Suspicion**

- Febrile
- Dysuria
- Frequency
- Flank Pain
- Hx of UTI

Male Risk Factors

- Temp ≥ 39°C
- Fever ≥ 2 days
- No source of infection
- Non-black Race

Female Risk Factors

- Age <12mo
- Temp ≥ 39°C
- Fever ≥ 2 days
- No source of infection
- White Race

! Bag Specimen
NOT Preferred
(consider with labial adhesions, or failed catheterizations)
NEVER send culture

Imaging Recommendations for patients >2months after 1st Febrile UTI

No imaging required

- o Prompt response to therapy (afebrile in 72 hrs)
- o Reliable outpatient follow up
- o Normal voiding pattern
- o No abdominal mass
- o Normal (<5mm pelvic dilation) 3rd trimester (>28 week) prenatal ultrasound

Consider Renal Ultrasound:

- o At clinical discretion in patient under 2 years
- o Bowel/bladder dysfunction


Renal Ultrasound recommended

- o Patient does not have adequate clinical response to appropriate treatment
- o Urosepsis/Severe infection associated with UTI
- o Recurrent UTIs
- o Unusual pathogens
- o Hypertension


Strongly consider Voiding Cystourethrogram (VCUG)

- o Renal U/S reveals hydronephrosis, scars, or findings of high grade VUR or obstructive uropathy
- o Urosepsis/Severe infection associated with UTI (postpone until infection has cleared)
- o Recurrent UTIs (especially if family hx)

ALGORITHM- UTI Empiric Therapy



ALGORITHM- UTI Culture Results



Second Line Therapy
 If resistant, phone follow-up is warranted. If patient is not improving, change to susceptible antimicrobial




TABLE OF CONTENTS

[Algorithm – UTI Testing](#)

[Algorithm – UTI Empiric Therapy](#)

[Algorithm – UTI Culture Results](#)

[Target Population](#)

[Background](#)

[Initial Evaluation](#)

[Clinical Management](#)

[Laboratory Studies | Imaging](#)

[Therapeutics](#)

[References](#)

[Clinical Improvement Team](#)

TARGET POPULATION

Inclusion Criteria

- Patients with presumed or documented UTI
- Patients aged >60 days old

Exclusion Criteria

- Need for immediate critical care/toxicity
- Known urologic anomalies
- Chronic/Complex conditions (ex. Spinabifida, self-cath, hardware, etc.)
- Immunocompromised

BACKGROUND

- UTIs are the most common cause of serious bacterial illness in children
- Recurrent UTI is a known cause chronic kidney disease in children
- Inappropriate management may result in severe or invasive illness
- Knowledge of risk factors and appropriate testing and interpretation of the results in proper clinical context is necessary for accurate diagnosis and treatment of UTI

Probability of UTI based on Number of Risk Factors

# Risk Factors	Males		Females
	Uncircumcised	Circumcised	
0	2.1%	0.2%	3.3%
1	4.1%	0.5%	5.1%
2	7.9%	1.0%	6.5%
3	14.7%	1.9%	11.4%
4	25.9%	3.7%	33.0%
5	--	--	45.0%

<p>Male Risk Factors</p> <ul style="list-style-type: none"> • Temp $\geq 39^{\circ}\text{C}$ • Fever ≥ 2 days • No source of infection • Non-black Race 	<p>Female Risk Factors</p> <ul style="list-style-type: none"> • Age <12mo • Temp $\geq 39^{\circ}\text{C}$ • Fever ≥ 2 days • No source of infection • White Race
---	---

INITIAL EVALUATION

Signs and Symptoms¹

Age group		Symptoms and signs Most common ———> Least common		
Infants younger than 3 months		Fever Vomiting Lethargy Irritability	Poor feeding Failure to thrive	Abdominal pain Jaundice Haematuria Offensive urine
Infants and children, 3 months or older	Preverbal	Fever	Abdominal pain Loin tenderness Vomiting Poor feeding	Lethargy Irritability Haematuria Offensive urine Failure to thrive
	Verbal	Frequency Dysuria	Dysfunctional voiding Changes to continence Abdominal pain Loin tenderness	Fever Malaise Vomiting Haematuria Offensive urine Cloudy urine

CLINICAL MANAGEMENT

Consider Urology Consult

- Urologic anomalies
- Recurrent UTI unresponsive to routine preventative measures
- Any questions or concerns regarding imaging, management, or prophylaxis

LABORATORY STUDIES | IMAGING

Laboratory Studies

Urinalysis (UA)

- Dipstick^{2, 3} or Standard

Table 2. Urinalysis Methods

	Dipstick	Microscopic
Mechanism	Dipstick	Centrifuge, No Gram stain
Pyuria	Leukocyte esterase: suggestive of UTI but not diagnostic	Equal to or greater than 5 WBC/HPF
Bacteriuria	Nitrite: highly specific but negative test not reliable *concentrated/first morning void specimens might make it more likely to observe nitrites when infection is present	Any bacteria\HPF (but correlates poorly with Gram stain and culture)
Sensitivity	Moderate- 88%, but not specific	Low - less than 81 %

Urine Culture (UC)

- Gold standard for diagnosis of UTI
- Most definitive result is >100,000 cfu of a single uropathogen
- CHCO lab does not report colony counts above or below 50,000 (only 10,000 or 100,000)
- However, multiple organisms and lower colony counts can reflect true UTI, particularly if:
 - The culture comes from a catheter specimen
 - There is high pre-test probability of UTI based on clinical history and urinalysis results (particularly if urine was nitrite positive)
 - One organism is a typical/common pathogen, e.g. *E.coli* and second organism is “other gram positive”
 - The patient has urinary tract anomalies
- Organisms considered contaminants (See [Table 5. Microorganisms Associated with UTI](#))
- Voided specimens can lead to false positive urine cultures. This is particularly true when there is low pre-test probability. When illness is severe or higher risk (e.g. in infancy), or an alternate diagnosis is more likely, a catheter specimen will lead to more reliable final culture results unless the urine is known to be nitrite positive.
- Test of cure/repeat urine cultures are not needed if responsive to therapy ^{4,5}

Table 4. *Microorganisms Associated with UTI at Children’s Hospital Colorado*

Frequency of organisms in urine culture by collection method at CHCO June 1, 2013 and May 31, 2015. Note frequency of “other gram positive” in cultures with multiple organisms. The vast majority of these cultures from catheter specimens also contain a typical uropathogen. Thus a typical pathogen (e.g. *E. coli*) plus “other gram positive” should be considered a positive culture for the pathogen, rather than a contaminated/unreliable specimen.

Organism	Catheter		Clean Catch	
	1 organism (% total)	% present in isolates with multiple organisms	1 organism (% total)	% present in isolates with multiple organisms
<i>Escherichia coli</i>	570 (66.28)	14.3%	814 (48.74)	3.1%
Other gram-positive	86 (10.00)	76.2%	592 (35.45)	92.3%
Other gram-negative rods	63 (7.33)	2.4%	75 (4.49)	1.9%
Other gram-negative enteric	42 (4.88)	2.4%	35 (2.10)	0.8%
<i>Enterococcus</i>	42 (4.88)	4.2%	20 (1.20)	0.2%
<i>Proteus</i>	22 (2.56)	0.6%	39 (2.34)	0.4%
<i>Staphylococcus</i>	19 (2.21)	0.00%	60 (3.59)	1.3%
<i>Streptococcus</i>	13 (1.51)	0.00%	31 (1.86)	0.00%
Other	3 (0.35)	0.00%	4 (0.24)	0.00%

Table 5. Microorganisms Associated with UTI

Gram-negative Organisms	Gram-positive Organisms	Fungal	Other organisms considered contaminants
<i>Escherichia coli</i> (most common, more than 80% first UTI)	<i>Enterococci</i>	<i>Candida</i> (usually in premature infants)	"Other Gram Positives" <i>Lactobacillus</i>
<i>Klebsiella</i> (next most common organism)	<i>Staphylococcus saprophyticus</i> (& others)		<i>Corynebacteria</i>
<i>Proteus</i>	<i>Staphylococcus aureus</i>		<i>Micrococcus</i> species
<i>Pseudomonas</i> (less than 2%)	Group B <i>streptococci</i>		<i>Diphtheroids</i>
<i>Enterobacter</i> (less than 2%)			<i>Bacillus</i>

Additional laboratory studies to consider based on clinical presentation

- Serum chemistries
 - BMP if concerns for renal involvement
- CBC, ESR, CRP are not routinely indicated
- Blood culture is not routinely indicated unless concern for bacteremia

Imaging

Imaging studies for identifying structure

- Renal Ultrasound²⁶
 - Non-invasive study dependent on examiner skill
 - Demonstrates anatomy of bladder, ureters, kidneys including renal size, and obstruction
 - No evaluation of renal function
 - Not adequate for assessment VUR
- CT Scan/ MRI
 - With IV contrast, useful in evaluation of renal parenchyma (both active infection and renal scarring). There is limited value in split renal function.
 - Useful in perinephric pathology
 - Useful in defining the degree and level of obstruction
 - CT poses the potential risk associated with ionizing radiation and risk from contrast on the kidneys
 - MRI often requires sedation in young children

Imaging studies for identifying VUR ²⁷

- Voiding cystourethrogram (VCUG)
 - Optimal initial study to demonstrate anatomy of lower tract disease (e.g. valves), and evaluate and grade VUR (postpone until infection has resolved).

Imaging studies for identifying scarring

- CT, MRI, or DMSA (only if indicated by urology)- should only be ordered in consultation with urology

THERAPEUTICS

Antibiotics

- See algorithm for recommendations (based on current resistance patterns seen in [Bugs and Drugs](#))
- Please note... Amoxicillin/clavulanate (Augmentin) and Amoxicillin are not recommended antibiotics for UTI treatment based on CHCO sensitivity data.
- If Cefixime is unavailable, alternative options would be cefpodoxime, cefuroxime, cefprozil, etc.

Analgesics

- Acetaminophen for comfort
- Ibuprofen or other NSAIDS should be used with caution if concern for renal injury
- Phenazopyridine for symptoms of dysuria for patients 6 years and older age. Educate families on urine discoloration when taking this drug.

REFERENCES

1. National Institute for Health and Care Excellence. Diagnosis of urinary tract infection in children. NICE Pathways. <http://pathways.nice.org.uk/pathways/urinary-tract-infection-in-children>. February 10, 2016. Accessed February 9, 2017.
2. Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. *Pediatrics* 2011;128:595-610.
3. Doley A, Nelligan M. Is a negative dipstick urinalysis good enough to exclude urinary tract infection in paediatric emergency department patients? *Emerg Med (Fremantle)* 2003;15:77-80.
4. Currie ML, Mitz L, Raasch CS, Greenbaum LA. Follow-up urine cultures and fever in children with urinary tract infection. *Arch Pediatr Adolesc Med* 2003;157:1237-40.
5. Oreskovic NM, Sembrano EU. Repeat urine cultures in children who are admitted with urinary tract infections. *Pediatrics* 2007;119:e325-9.
6. Levine DA, Platt SL, Dayan PS, Macias CG, et al. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. *Pediatrics*. 2004;113(6):1728-34. <http://proxygw.wrlc.org/login?url=http://search.proquest.com/docview/228418980?accountid=11243>.
7. Shaikh N, Hoberman A, Wise B, et al. Dysfunctional elimination syndrome: is it related to urinary tract infection or vesicoureteral reflux diagnosed early in life? *Pediatrics* 2003;112:1134-7.
8. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev* 2012;10:CD001321.
9. Salo J, Uhari M, Helminen M, et al. Cranberry juice for the prevention of recurrences of urinary tract infections in children: a randomized placebo-controlled trial. *Clin Infect Dis* 2012;54:340-6.
10. Lee SJ, Shim YH, Cho SJ, Lee JW. Probiotics prophylaxis in children with persistent primary vesicoureteral reflux. *Pediatr Nephrol* 2007;22:1315-20.
11. Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. *Arch Dis Child* 2005;90:853-8.
12. Jagannath VA, Fedorowicz Z, Sud V, Verma AK, Hajebrahimi S. Routine neonatal circumcision for the prevention of urinary tract infections in infancy. *Cochrane Database Syst Rev* 2012;11:CD009129.
13. Finnell SM, Carroll AE, Downs SM. Technical report-Diagnosis and management of an initial UTI in febrile infants and young children. *Pediatrics* 2011;128:e749-70.
14. Gorelick MH, Hoberman A, Kearney D, Wald E, Shaw KN. Validation of a decision rule identifying febrile young girls at high risk for urinary tract infection. *Pediatr Emerg Care* 2003;19:162-4.
15. Shaikh N, Morone NE, Lopez J, et al. Does this child have a urinary tract infection? *Jama* 2007;298:2895-904.
16. Michael M, Hodson EM, Craig JC, Martin S, Moyer VA. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children. *Cochrane Database Syst Rev* 2003:CD003966. Hodson EM, Willis NS, Craig JC. Antibiotics for acute pyelonephritis in children. *Cochrane Database Syst Rev* 2007:CD003772.
17. Nagler EV, Williams G, Hodson EM, Craig JC. Interventions for primary vesicoureteric reflux. *Cochrane Database Syst Rev* 2011:CD001532.
18. Craig JC, Simpson JM, Williams GJ, et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. *N Engl J Med* 2009;361:1748-59.
19. Montini G, Rigon L, Zucchetta P, et al. Prophylaxis after first febrile urinary tract infection in children? A multicenter, randomized, controlled, noninferiority trial. *Pediatrics* 2008;122:1064-71.
20. Pennesi M, Travan L, Peratoner L, et al. Is antibiotic prophylaxis in children with vesicoureteral reflux effective in preventing pyelonephritis and renal scars? A randomized, controlled trial. *Pediatrics* 2008;121:e1489-94.
21. Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren R. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. *Jama* 2007;298:179-86.
22. Ismaili K, Hall M, Piepsz A, et al. Primary vesicoureteral reflux detected in neonates with a history of fetal renal pelvis dilatation: a prospective clinical and imaging study. *J Pediatr* 2006;148:222-7.
23. Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal scarring in children with a first urinary tract infection: a systematic review. *Pediatrics* 2010;126:1084-91.
24. Garin EH, Olavarria F, Garcia Nieto V, Valenciano B, Campos A, Young L. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. *Pediatrics* 2006;117:626-32.
25. Jodal U, Smellie JM, Lax H, Hoyer PF. Ten-year results of randomized treatment of children with severe vesicoureteral reflux. Final report of the International Reflux Study in Children. *Pediatr Nephrol* 2006;21:785-92.

26. Wheeler D, Vimalachandra D, Hodson EM, Roy LP, Smith G, Craig JC. Antibiotics and surgery for vesicoureteric reflux: a meta-analysis of randomised controlled trials. *Arch Dis Child* 2003;88:688-94.
27. Jahnukainen T, Honkinen O, Ruuskanen O, Mertsola J. Ultrasonography after the first febrile urinary tract infection in children. *Eur J Pediatr* 2006;165:556-9.
28. Gordon I, Barkovics M, Pindoria S, Cole TJ, Woolf AS. Primary vesicoureteric reflux as a predictor of renal damage in children hospitalized with urinary tract infection: a systematic review and meta-analysis. *J Am Soc Nephrol* 2003;14:739-44.
29. Classifying recommendations for clinical practice guidelines. *Pediatrics* 2004;114:874-7.

CLINICAL IMPROVEMENT TEAM MEMBERS

Rakesh Mistry, MD | Emergency Medicine

James Gaensbauer, MD | Infectious Disease

Leigh Ann Bakel, MD | Hospitalist

Lee Stigler, MD | Hospitalist

Sharisse Rehring, MD | Kaiser Physician

John Strain, MD | Radiologist

Kimberly O'Hara, MD | Hospitalist

Christine Jelinek, MD | Pediatrician

Christina Osborne, MD | Infectious Disease

Lalit Bajaj, MD | Emergency Medicine

David Chung, MD | Hospitalist

Sarah Scott, PNP | Emergency PNP

Patrick Burchett, PA | Emergency PA

Sarah Schmidt, MD | Emergency Medicine

Ryan Lowe, PharmD | Clinical Pharmacist- Kaiser

Jason Child, PharmD | Clinical Pharmacist

Elaine Dowell | Laboratory

Melisha Hanna, MD | Nephrology


Kaylee Wickstrom, RN | CE Process Improvement Specialist

APPROVED BY

Antimicrobial Stewardship Committee – March 2017

Clinical Care Guideline and Measures Review Committee – March 20, 2017

Pharmacy & Therapeutics Committee – April 6, 2017

MANUAL/DEPARTMENT	Clinical Care Guidelines/Quality
ORIGINATION DATE	December 12, 2011
LAST DATE OF REVIEW OR REVISION	April 6, 2017
APPROVED BY	 Lalit Bajaj, MD, MPH Medical Director, Clinical Effectiveness

REVIEW | REVISION SCHEDULE

Scheduled for full review on April 6, 2021

Clinical pathways are intended for informational purposes only. They are current at the date of publication and are reviewed on a regular basis to align with the best available evidence. Some information and links may not be available to external viewers. External viewers are encouraged to consult other available sources if needed to confirm and supplement the content presented in the clinical pathways. Clinical pathways are not intended to take the place of a physician's or other health care provider's advice, and is not intended to diagnose, treat, cure or prevent any disease or other medical condition. The information should not be used in place of a visit, call, consultation or advice of a physician or other health care provider. Furthermore, the information is provided for use solely at your own risk. CHCO accepts no liability for the content, or for the consequences of any actions taken on the basis of the information provided. The information provided to you and the actions taken thereof are provided on an "as is" basis without any warranty of any kind, express or implied, from CHCO. CHCO declares no affiliation, sponsorship, nor any partnerships with any listed organization, or its respective directors, officers, employees, agents, contractors, affiliates, and representatives.

Discrimination is Against the Law. Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Children's Hospital Colorado does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Children's Hospital Colorado provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters, written information in other formats (large print, audio, accessible electronic formats, other formats). Children's Hospital Colorado provides free language services to people whose primary language is not English, such as: Qualified interpreters, information written in other languages.

If you need these services, contact the Medical Interpreters Department at 720.777.9800.

If you believe that Children's Hospital Colorado has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Corporate Compliance Officer, 13123 E 16th Avenue, B450, Aurora, Colorado 80045, Phone: 720.777.1234, Fax: 720.777.7257, corporate.compliance@childrenscolorado.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Corporate Compliance Officer is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 1-800-368-1019, 800-537-7697 (TDD) Complaint forms are available at www.hhs.gov/ocr/office/file/index.html.

Children's Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-720-777-9800.

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-720-777-9800.

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-720-777-9800 번으로 전화해 주십시오.

注意: 如果您使用繁體中文, 您可以免費獲得語言援助服務。請致電1-720-777-9800。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-720-777-9800.

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም አርዳታ ድርጅቶቹ: በነጻ ሊያገዝዎት ተዘጋጅተዋል። ወደ ሚከተለው ቁጥር ይደውሉ 1-720-777-9800 (መስማት ለተሳናቸው ፡ ማስታወሻ: إذا كنت تتحدث انكر اللغة، فإن خدمات المساعدة اللغوية تتوفر لك بالمجان. اتصل برقم 720-777-9800 (رقم)

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-720-777-9800.

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-720-777-9800.

ध्यान दनु होस्तपाइले नेपाल बोलनहनछ भन तपाइको निम्त भाषा सहायता सवाहरू नःशलकूपमा उपलब्ध छ । फोन गनु होसरू 1-720-777-9800 ।

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-720-777-9800.

注意事項: 日本語を話される場合、無料の言語支援をご利用いただけます。1-720-777-9800 まで、お電話にてご連絡ください。

Nti: O buru na asy lbo, asyus aka oasuy n'efu, defu, aka. Call 1-720-777-9800.